Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
NAFLD is the world’s most common chronic liver disease, and its increasing prevalence parallels the global rise in diabetes and obesity. It is characterised by fat accumulation in the liver evolving to non-alcoholic steatohepatitis (NASH), an inflammatory subtype that can lead to liver fibrosis and cirrhosis. Currently, there is no effective pharmacotherapeutic treatment for NAFLD. Treatment is therefore based on lifestyle modifications including changes to diet and exercise, although it is unclear what the most effective form of intervention is. The aim of this review, then, is to discuss the role of specific nutrients and the effects of different dietary interventions on NAFLD. It is well established that an unhealthy diet rich in calories, sugars, and saturated fats and low in polyunsaturated fatty acids, fibre, and micronutrients plays a critical role in the development and progression of this disease. However, few clinical trials have evaluated the effects of nutrition interventions on NAFLD. We, therefore, summarise what is currently known about the effects of macronutrients, foods, and dietary patterns on NAFLD prevention and treatment. Most current guidelines recommend low-calorie, plant-based diets, such as the Mediterranean diet, as the most effective dietary pattern to treat NAFLD. More clinical trials are required, however, to identify the best evidence-based dietary treatment approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 5×
“As mentioned before, its incidence is growing worldwide in parallel with overweight, obesity, T2DM, and MetS [5,13,16].”
BackgroundInfluentialEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616 · cited 14×
“As mentioned before, its incidence is growing worldwide in parallel with overweight, obesity, T2DM, and MetS [5,13,16].”
BackgroundInfluentialMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 3×
“The example of the USA demonstrates the growing seriousness of NAFLD: there it is the second-leading indication for HCC-related transplantation and the third most common cause for liver transplantation (and on track to become the most common cause) [14,63].”
BackgroundGlobal perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858 · cited 2×
“Today, added sugar intake makes up 15% of total daily calories in the average Western diet [17].”
BackgroundTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020 · cited 1×
“Bacterial endotoxins can go through the portal vein to the liver, inducing inflammation and IR and promoting the development of fatty liver [41].”
BackgroundTriggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Schwingshackl, L., Hoffmann, G., Lampousi, A.-M., Knüppel, S., Iqbal, K., Schwedhelm, C., Bechthold, A., Schlesinger, S., & Boeing, H. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0246-y · Cited by 799
Bueno, N. B., de Melo, I. S. V., de Oliveira, S. L., & da Rocha Ataide, T. (2013) · British Journal of Nutrition · doi:10.1017/s0007114513000548 · Cited by 778 · cited 1×
“The KD is a powerful tool to induce weight loss and achieve greater long-term weight reduction, compared to low-fat diets [134].”
BackgroundMolecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Hoyles, L., Fernández-Real, J.-M., Federici, M., Serino, M., Abbott, J., Charpentier, J., Heymes, C., Luque, J. L., Anthony, E., Barton, R. H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0061-3 · Cited by 720 · cited 2×
“The recommended cut-offs are as follows: FLI < 30 to rule out (87% sensitivity) and FLI ≥ 60 to rule in hepatic steatosis (specificity 86%) [38,39].”
BackgroundNAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643 · cited 10×
“As mentioned before, its incidence is growing worldwide in parallel with overweight, obesity, T2DM, and MetS [5,13,16].”
BackgroundInfluentialFructose metabolism and metabolic disease
Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96702 · Cited by 561
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538 · cited 1×
“The follow-up period in these trials is short (mostly 4 weeks or less), whereas we know from animal models that fatty liver develops after at least 8–24 weeks on a high-fructose diet [92].”
BackgroundA journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses
Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., Panagiotakos, D., & Giugliano, D. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008222 · Cited by 501 · cited 10×
“As mentioned before, its incidence is growing worldwide in parallel with overweight, obesity, T2DM, and MetS [5,13,16].”
BackgroundInfluentialBjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490 · cited 1×
“Additionally, a 10-week randomised trial (n = 67) comparing two isocaloric diets containing Omega-6 PUFAs or SFAs showed that Omega-6 PUFAs supplementation caused a reduction in hepatic steatosis, insulin levels, and inflammatory markers when compared with SFAs, though no changes in weight were observed [108].”
BackgroundLuukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428 · cited 1×
“Furthermore, SFAs induced IR and endotoxemia and significantly increased multiple plasma ceramides [109].”
BackgroundHarris, L., Hamilton, S., Azevedo, L. B., Olajide, J., De Brún, C., Waller, G., Whittaker, V., Sharp, T., Lean, M., Hankey, C., et al. (2018) · JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2016-003248 · Cited by 319 · cited 1×
“A recent systematic review and meta-analysis that included interventional trials concluded that IF was comparable to continuous energy restriction for short-term weight loss in individuals with overweight and obesity [166].”
BackgroundChiu, S., Sievenpiper, J. L., de Souza, R. J., Cozma, A. I., Mirrahimi, A., Carleton, A. J., Ha, V, Di Buono, M., Jenkins, A. L., Leiter, L. A., et al. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.8 · Cited by 314 · cited 1×
“However, these studies have some limitations [88,89,91].”
Haufe, S., Engeli, S., Kast, P., Böhnke, J., Utz, W., Haas, V., Hermsdorf, M., Mähler, A., Wiesner, S., Birkenfeld, A. L., et al. (2011) · Hepatology · doi:10.1002/hep.24242 · Cited by 307
Schwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.028 · Cited by 298 · cited 2×
“The only consistent observations from the data are that greater amounts of Proteobacteria (especially Escherichia coli and other Enterobacteriaceae spp) and lower quantity of Bacteroidetes are observed in patients suffering from NAFLD, whereas a decreased Firmicutes:Bacteroidetes ratio is also noted [44,45].”
BackgroundZelber-Sagi, S., Ivancovsky-Wajcman, D., Fliss Isakov, N., Webb, M., Orenstein, D., Shibolet, O., & Kariv, R. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.015 · Cited by 297 · cited 1×
“NAFLD has also been associated with red and processed meat consumption even when intakes are low [130,131].”
BackgroundBarnard, N. D., Levin, S. M., & Yokoyama, Y. (2015) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.11.016 · Cited by 266
Soltani, S., Shirani, F., Chitsazi, M. J., & Salehi‐Abargouei, A. (2016) · Obesity Reviews · doi:10.1111/obr.12391 · Cited by 251 · cited 1×
“Furthermore, a systematic review and meta-analysis reported that DASH might be a better choice for weight management and reduction than other low-energy diets [159].”
BackgroundBozzetto, L., Prinster, A., Annuzzi, G., Costagliola, L., Mangione, A., Vitelli, A., Mazzarella, R., Longobardo, M., Mancini, M., Vigorito, C., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0033 · Cited by 227 · cited 1×
“Some small, short-term randomised clinical trials have also shown clear positive results [120,121].”
BackgroundProperzi, C., O'Sullivan, T. A., Sherriff, J. L., Ching, H. L., Jeffrey, G. P., Buckley, R. F., Tibballs, J., MacQuillan, G. C., Garas, G., & Adams, L. A. (2018) · Hepatology · doi:10.1002/hep.30076 · Cited by 227
Sevastianova, K., Santos, A., Kotronen, A., Hakkarainen, A., Makkonen, J., Silander, K., Peltonen, M., Romeo, S., Lundbom, J., Lundbom, N., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.038695 · Cited by 211 · cited 2×
“Even short-term interventions demonstrated that consumption of a high-fructose diet (HFruD) had a significant lipogenic effect on the liver [85].”
BackgroundTurner-McGrievy, G. M., Davidson, C. R., Wingard, E. E., Wilcox, S., & Frongillo, E. A. (2015) · Nutrition · doi:10.1016/j.nut.2014.09.002 · Cited by 207 · cited 18×
“Additionally, a recent meta-analysis found evidence that diabetic patients with NAFLD had more than twofold higher risk for CVD, compared to patients without NAFLD (odds ratio [OR] 2.20, 95% confidence interval [CI] 1.67–2.90), suggesting a synergistic effect between NAFLD and T2DM on the risk of CVD.”
BackgroundInfluentialYu, J., Marsh, S., Hu, J., Feng, W., & Wu, C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2862173 · Cited by 199
Choi, Y. J., Jeon, S.-M., & Shin, S. (2020) · Nutrients · doi:10.3390/nu12072005 · Cited by 193 · cited 1×
“of total daily caloric intake (20–50 g of carbohydrate/day) [133], although the specific macronutrient composition may vary.”
BackgroundAdvantages and Disadvantages of the Ketogenic Diet: A Review Article
Batch, J. T., Lamsal, S. P., Adkins, M., Sultan, S., & Ramirez, M. N. (2020) · Cureus · doi:10.7759/cureus.9639 · Cited by 181 · cited 1×
“Nevertheless, some authors suggest that these effects are lost in the long term (>12 months) [137].”
BackgroundKatsagoni, C. N., Papatheodoridis, G. V., Ioannidou, P., Deutsch, M., Alexopoulou, A., Papadopoulos, N., Papageorgiou, M.-V., Fragopoulou, E., & Kontogianni, M. D. (2018) · British Journal of Nutrition · doi:10.1017/s000711451800137x · Cited by 167 · cited 1×
“In fact, most guidelines recommend the MedDiet as the best dietary pattern against liver steatosis [146,147].”
BackgroundSobrecases, H., Lê, K.-A., Bortolotti, M., Schneiter, P., Ith, M., Kreis, R., Boesch, C., & Tappy, L. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.003 · Cited by 161 · cited 1×
“For instance, daily consumption of SSBs for 6 months by overweight subjects (n = 47) resulted in the accumulation of liver fat as proven by magnetic resonance spectroscopy [84].”
BackgroundZhou, Y.-Y., Zhou, X.-D., Wu, S.-J., Hu, X.-Q., Tang, B., Poucke, S. V., Pan, X.-Y., Wu, W.-J., Gu, X.-M., Fu, S.-W., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001075 · Cited by 125 · cited 1×
“However, it remains uncertain whether NAFLD is associated with CVD as a result of coexisting cardiovascular factors, or if it independently raises CVD risk as a proatherogenic stimulus [61].”
BackgroundChen, H., Wang, J., Li, Z., Lam, C. W. K., Xiao, Y., Wu, Q., & Zhang, W. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16122192 · Cited by 112
Park, J., Seo, Y.-G., Paek, Y.-J., Song, H. J., Park, K. H., & Noh, H.-M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154336 · Cited by 93 · cited 1×
“Intermittent fasting (IF) is an emerging nutritional approach for weight loss and for the management of metabolic diseases and is considered an alternative to continuous calorie restriction [164].”
BackgroundEffects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Tang, Y., Huang, J., Zhang, W. Y., Qin, S., Yang, Y. X., Ren, H., Yang, Q.-B., & Hu, H. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878046 · Cited by 85 · cited 1×
“Supplementation with probiotics, prebiotics, or synbiotics has been proven to treat dysbiosis and improve NAFLD [49].”
Background
Cited by
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Benedé-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2331460 · Cited by 242
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes
Finer, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14569 · Cited by 45
Huggett, Z. J., Smith, A., De Vivo, N., Gomez, D., Jethwa, P., Brameld, J. M., Bennett, A., & Salter, A. M. (2022) · Nutrients · doi:10.3390/nu15010040 · Cited by 37
“However, diet is also believed to play a significant role in its development, with diets rich in total energy, high saturated fatty acid and simple sugars all reported to increase hepatic steatosis [5].”
BackgroundDiet-microbiome interactions in cancer
Abdeen, S. K., Mastandrea, I., Stinchcombe, N., Puschhof, J., & Elinav, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.013 · Cited by 36
Metadata
- Authors
- Vancells Lujan, P., Viñas Esmel, E., & Sacanella Meseguer, E.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2021-04-24
- Volume
- 13
- Issue
- 5
- Pages
- 1442
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W3157134902
- Cited by
- 209
- References
- 40
- FWCI
- 20.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.